Milestone Asset Management LLC Makes New $861,000 Investment in Prestige Consumer Healthcare Inc. $PBH

Milestone Asset Management LLC bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 13,803 shares of the company’s stock, valued at approximately $861,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. UMB Bank n.a. raised its position in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after buying an additional 250 shares during the period. Maseco LLP acquired a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $27,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Prestige Consumer Healthcare during the second quarter worth $46,000. Finally, First Horizon Advisors Inc. lifted its stake in shares of Prestige Consumer Healthcare by 294.1% during the second quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock valued at $48,000 after acquiring an additional 447 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on PBH. Canaccord Genuity Group dropped their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Oppenheimer dropped their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective on the stock in a research note on Wednesday, September 24th. Finally, Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $85.33.

Prestige Consumer Healthcare Stock Up 0.2%

Prestige Consumer Healthcare stock opened at $62.42 on Thursday. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 1.96 and a beta of 0.39. The company’s 50 day simple moving average is $60.76 and its 200 day simple moving average is $67.61. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.10. The company had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The business’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same period last year, the business posted $1.09 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the transaction, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).